BMJ Case Reports 2009; doi:10.1136/bcr.11.2008.1214
  • Novel treatment (new drug/intervention; established drug/procedure in new situation)

Treating subglottic haemangioma with methylprednisolone and interferonα-2a

  1. Suprabha Kumari Patnaik,
  2. Vishal Sondhi
  1. Military Hospital, Pediatrics, Cantt, Saugor, Madhya Pradesh, 470001, India
  1. Vishal Sondhi, dr.sondhi{at}
  • Published 7 April 2009


Subglottic haemangiomas are benign vascular malformations presenting in early infancy with respiratory distress due to progressive airway obstruction. The lesion, after undergoing proliferation during the first few months, naturally involutes by an age of 2–3 years. Due to high incidence of mortality, therapy should be initiated immediately. Multiple therapeutic options, such as steroids, interferon, surgery and laser ablation, are available but the best treatment is controversial. This report describes an infant presenting with respiratory distress and cutaneous haemangioma who was detected to have airway obstructive haemangioma from the subglottis to the carina. Due to the massive size, surgical and laser ablation could not be exercised. Also, the infant showed no response to dexamethasone, prednisolone or interferon. Following failure of these modalities, the infant was successfully managed with concurrent administration of daily interferon and pulse methylprednisolone. The regime resulted in rapid shrinkage of the haemangioma and resolution of symptoms, with no recurrence up to 24 months of age.


  • Competing interests: none.

  • Patient consent: Patient/guardian consent was obtained for publication.

Register for free content

The full text of all Editor's Choice articles and summaries of every article are free without registration

The full text of Images in ... articles are free to registered users

Only fellows can access the full text of case reports (apart from Editor's Choice) - become a fellow today, or encourage your institution to, so that together we can grow and develop this resource

Don't forget to sign up for content alerts so you keep up to date with all the case reports as they are published, and let us know what you think by commenting on the Editor's blog

Navigate This Article